Vietnam imported pharmaceutical products to the tune of US$284 million in November, down from US$350 million in October, a change of -18.96 percent, according to preliminary data from Vietnam’s General Department of Customs.
Year to date, Vietnam had imported US$3,844 million worth of pharmaceutical products by the end of November.
The USA accounted for US$39 million worth of Vietnam’s pharmaceutical products imports in November. This was down from US$71 million in pharmaceutical products imports in October, a change of 45.20 percent. Year to date, the USA has shipped US$485 million worth of pharmaceutical products to Vietnam.
After the USA was Italy making up US$31 million worth of Vietnam’s pharmaceutical products imports in November. This was up from US$24 million in pharmaceutical products imports in October, a change of 33.21 percent. Year to date, Italy has shipped US$282 million worth of pharmaceutical products to Vietnam.
Next was France contributing US$31 million worth of Vietnam’s pharmaceutical products imports in November. This was down from US$41 million in pharmaceutical products imports in October, a change of 23.10 percent. Year to date, France has shipped US$449 million worth of pharmaceutical products to Vietnam.
Following France was Germany representing US$24 million worth of Vietnam’s pharmaceutical products imports in November. This was down from US$31 million in pharmaceutical products imports in October, a change of 22.07 percent. Year to date, Germany has shipped US$368 million worth of pharmaceutical products to Vietnam.
Rounding out the top five was India constituting US$18 million worth of Vietnam’s pharmaceutical products imports in November. This was down from US$23 million in pharmaceutical products imports in October, a change of 23.06 percent. Year to date, India has shipped US$264 million worth of pharmaceutical products to Vietnam.
Learn more about accessing Vietnam’s consumer market→
Vietnam imports of pharmaceutical products in November, US$m
| November | October | MoM | YTD | |
| Total | 283.66 | 350.02 | -18.96% | 3,844.07 |
| Other | 83.02 | 109.64 | -24.28% | 1,399.61 |
| USA | 38.93 | 71.03 | -45.20% | 484.88 |
| Italy | 31.36 | 23.54 | 33.21% | 282.23 |
| France | 31.18 | 40.54 | -23.10% | 448.90 |
| Germany | 23.79 | 30.52 | -22.07% | 367.54 |
| India | 17.97 | 23.36 | -23.06% | 263.52 |
| Ireland | 15.63 | 9.35 | 67.08% | 179.31 |
| South Korea | 15.37 | 15.64 | -1.73% | 128.99 |
| Spain | 10.48 | 8.23 | 27.39% | 112.40 |
| Austria | 8.76 | 7.11 | 23.24% | 94.18 |
| UK | 7.17 | 11.04 | -35.10% | 82.51 |
| China | 6.97 | 5.65 | 23.45% | 55.11 |
| Thailand | 6.62 | 5.15 | 28.72% | 65.57 |
| Netherlands | 5.86 | 3.57 | 64.18% | 82.79 |
| Belgium | 4.65 | 19.48 | -76.11% | 256.71 |
| Japan | 4.39 | 7.05 | -37.73% | 54.80 |
| Sweden | 3.46 | 2.89 | 19.91% | 141.57 |
| Switzerland | 2.91 | 9.06 | -67.93% | 108.22 |
| Australia | 2.73 | 3.24 | -15.93% | 44.69 |
| Hungary | 2.48 | 2.40 | 3.42% | 36.44 |
| Poland | 2.32 | 2.51 | -7.45% | 40.21 |
| Cyprus | 1.88 | 2.54 | -26.13% | 22.87 |
| Taiwan | 1.80 | 1.82 | -1.13% | 22.42 |
| Denmark | 1.61 | 0.93 | 72.88% | 25.33 |
| Indonesia | 1.43 | 3.77 | -62.16% | 17.68 |
| Pakistan | 1.35 | 0.52 | 161.08% | 8.20 |
| Singapore | 1.19 | 0.73 | 63.32% | 14.10 |
| Turkey | 1.10 | 1.40 | -21.86% | 20.94 |
| Lithuania | 0.88 | 0.89 | -1.04% | 4.88 |
| Malaysia | 0.84 | 2.94 | -71.43% | 10.23 |
| Russia | 0.71 | 0.40 | 77.88% | 39.33 |
| Canada | 0.53 | 1.27 | -58.38% | 14.89 |
| Bangladesh | 0.18 | 0.96 | -81.46% | 8.72 |
| Philippines | 0.10 | 0.13 | -19.29% | 0.62 |
| Argentina | 0.07 | 0.03 | 114.94% | 5.18 |
Listed pharmaceutical products companies
These companies are listed on the Ho Chi Minh City Stock Exchange.
Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company
DBD closed at VND 48,800 on Tuesday up 0.35 percent with 159,000 shares traded, worth VND 775 million.
Foreign ownership in DBD is currently capped at 100.0 percent, with current foreign ownership sitting at 15.1 percent.
Ben Tre Pharmaceutical JSC
Ben Tre Pharmaceutical JSC (DBT) produces and distributes generic drugs, supplements, and medical products across Vietnam.
DBT closed at VND 11,000 on Tuesday down 0 percent with 25,000 shares traded, worth VND 28 million.
Foreign ownership in DBT is currently capped at 0.0 percent, with current foreign ownership sitting at 0.0 percent.
Cuu Long Pharmaceutical Joint Stock Corporation
Cuu Long Pharmaceutical Joint Stock Corporation (DCL) manufactures and distributes pharmaceutical and healthcare products under the Traphaco Group.
DCL closed at VND 42,000 on Tuesday up 0.6 percent with 3,853,000 shares traded, worth VND 16,065 million.
Foreign ownership in DCL is currently capped at 0.0 percent, with current foreign ownership sitting at 0.0 percent.
Explore opening a trading account in Vietnam→
Vietnam pharmaceutical products news
Recent developments include:
South Korea medical container factory
HuM&C, a healthcare materials subsidiary of Huons Group, has launched its first overseas medical container factory in Hung Yen Province, Vietnam, with full-scale production starting in the second quarter of 2025.
The Vietnam facility, operated by HuM&C Vina, can produce 60 million vials and 40 million cartridges annually, positioning it as a global production hub.
Healthcare industry report
Vietnam Report has released the results of a survey showing 60.7 percent of companies reported higher revenue in the first nine months of 2025, but only 42.9 percent saw profit growth, reflecting tougher competition in the sector.
Healthcare demand remains the strongest growth driver, with private hospital investment and M&A activity rising as foreign and domestic capital targets a long-term market, the report says.
See the latest Vietnam news headlines→
Vietnam’s pharmaceutical products industry
Vietnam’s pharmaceutical products industry is expanding steadily, driven by rising healthcare demand, an ageing population, and increased public and private health spending.
Domestic manufacturers focus mainly on generics and over-the-counter medicines, while Vietnam remains reliant on imported patented drugs and active pharmaceutical ingredients, prompting policy efforts to boost local production and technology transfer.